Delafloxacin for the treatment of respiratory and skin infections

Bibliography

• Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12
   PubMed Web of Science ®Google Scholar
• Hersh AL, Newland JG, Beekmann SE, et al. Unmet medical need in infectious diseases. Clin Infect Dis 2012;54:1677-8
   PubMed Web of Science ®Google Scholar
• Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 2011;86:250-9
   PubMed Web of Science ®Google Scholar
• Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011;53:60-7
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013;13:785-96
   PubMed Web of Science ®Google Scholar
• DeLeo FR, Chambers HF. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J Clin Invest 2009;119:2464-74
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-402
   PubMed Web of Science ®Google Scholar
• Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-44
   PubMed Web of Science ®Google Scholar
• Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004;38:1700-5
   PubMed Web of Science ®Google Scholar
• Doern GV, Heilmann KP, Huynh HK, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001;45:1721-9
   PubMed Web of Science ®Google Scholar
• Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(Suppl 2):S81-93
   PubMed Web of Science ®Google Scholar
• Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998;279:593-8
   PubMed Web of Science ®Google Scholar
• Almer LS, Shortridge VD, Nilius AM, et al. Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2002;43:225-32
   PubMed Web of Science ®Google Scholar
• Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999;341:233-9
   PubMed Web of Science ®Google Scholar
• Ho PL, Yung RW, Tsang DN, et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother 2001;48:659-65
   PubMed Web of Science ®Google Scholar
• Takahashi H, Hayakawa I, Akimoto T. [The history of the development and changes of quinolone antibacterial agents]. Yakushigaku Zasshi 2003;38:161-79
   PubMedGoogle Scholar
• Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resist Updat 1999;2:38-55
   PubMed Web of Science ®Google Scholar
• Hooper DC. New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis 2000;30:243-54
   PubMed Web of Science ®Google Scholar
• Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010;65(Suppl 3):iii35-44
   PubMed Web of Science ®Google Scholar
• Falagas ME, Matthaiou DK, Bliziotis IA. Systematic review: fluoroquinolones for the treatment of intra-abdominal surgical infections. Aliment Pharmacol Ther 2007;25:123-31
   PubMed Web of Science ®Google Scholar
• Everett MJ, Jin YF, Ricci V, Piddock LJ. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother 1996;40:2380-6
   PubMed Web of Science ®Google Scholar
• Dalhoff A. Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdiscip Perspect Infect Dis 2012;2012:976273
   PubMedGoogle Scholar
• Dalhoff A. Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance. Infection 1994;22(Suppl 2):S111-21
   PubMedGoogle Scholar
• Duffy EM, DeVito JA, Remy J, Burak ES. Delafloxacin chemical properties lead to increased potency against Gram-positive pathogens, including quinolone-resistant pathogens (II) [abstract E-182]. Presented at 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 12 – 15 September 2010; Boston, MA. Available from: http://www.melinta.com/uploads/Rib-X_Delafloxacin_ICAAC-2010_E-182.pdf
   Google Scholar
• Ohshita J, Yazaki A. In vitro studies with WQ-3034, a newly sinthesized acidic fluoroquinolone. Presented at 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 28th – October 1st 1997; Toronto, CA
   Google Scholar
• Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother 2011;55:649-58
   PubMed Web of Science ®Google Scholar
• Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997;61:377-92
   PubMed Web of Science ®Google Scholar
• Zhao X, Xu C, Domagala J, Drlica K. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci USA 1997;94:13991-6
   PubMed Web of Science ®Google Scholar
• Nilius AM, Shen LL, Hensey-Rudloff D, et al. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother 2003;47:3260-9
   PubMed Web of Science ®Google Scholar
• Almer LS, Hoffrage JB, Keller EL, et al. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms. Antimicrob Agents Chemother 2004;48:2771-7
   PubMed Web of Science ®Google Scholar
• Remy JM, Tow-Keogh CA, McConnell TS, et al. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Chemother 2012;67:2814-20
   PubMed Web of Science ®Google Scholar
• Tow-Keogh C, McConnell T, Remy J, et al. Anti-MRSA Properties of Delafoxacin: Mutant Analysis and Characterization [absract C1-1363]. Presented at 49th Annual Interscience Conference on Antimcrobial Agents and Chemotherapy; 12 – 15 September 2009; San Francisco, CA, USA. Available from: http://www.melinta.com/uploads/Rib-X_Delafloxacin_ICAAC-2009_C1-1363.pdf
   Google Scholar
• Burak E, Hopkins S, Pillar C, Lawrence L. In vitro activity of delafoxacin against methicillin-resistant staphylococcus aureus from the United States, Europe and Asia [abstract P1080]. Presented at 19th ECCMID; 16 – 19 May 2009; Helsinki, Finland. Available from: http://www.melinta.com/uploads/Rib-X_Delafloxacin_ECCMID-2009_P-1080.pdf
   Google Scholar
• Bauer J, Siala W, Tulkens PM, Van Bambeke F. A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrob Agents Chemother 2013;57:2726-37
   PubMed Web of Science ®Google Scholar
• So W, Crandon JL, Nicolau DP. Effects of urine matrix and pH on the potency of delafloxacin and ciprofloxacin against urogenic E. coli and K. pneumoniae. Presented at 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 5 – 9 September 2014; Washington. Available from: http://www.icaaconline.com/php/icaac2014abstracts/data/papers/2014/F-275.htm
   Google Scholar
• McEwen A, Lawrence L, Wood S, et al. Metabolism and mass balance of delafloxacin in healthy human volunteers following intravenous administration [abstracts A-1956]. Presented at 52th Annual Interscience Conference on Antimcrobial Agents and Chemotherapy; 9 – 12 September 2012; San Francisco, CA, USA. Available from: http://www.melinta.com/uploads/Rib-X_Delafloxacin_ICAAC-2012_A-1956.pdf
   Google Scholar
• Hoover R, Lawrence L, Benedict M, et al. Pharmacokinetics and relative bioavailability of intravenous and oral formulations of delafloxacin (DLX) in healthy subjects. Presented at 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 5 – 9 September 2014; Washington. Available from: http://www.icaaconline.com/php/icaac2014abstracts/data/papers/2014/A-056a.htm
   Google Scholar
• A phase 2 exploratory study of objective endpoints in subjects with acute bacterial skin and skin structure infections treated with delafloxacin, vancomycin, or linezolid. Identifier NCT01283581 Available from: https://www.clinicaltrials.gov/ct2/show/NCT01283581?term=NCT01283581&rank=1 [Accessed 28 November 2014]
   Google Scholar
• A phase 3, multicenter, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of delafloxacin compared with vancomycin + aztreonam in patients with acute bacterial skin and skin structure infections. Identifier NCT01811732 Available from: https://www.clinicaltrials.gov/ct2/show/NCT01811732?term=NCT01811732&rank=1 [Accessed 8 November 2014]
   Google Scholar
• A phase 3, multicenter, randomized, double-blind, active controlled study to evaluate the efficacy + safety of IV + Oral delafloxacin compared with vancomycin + aztreonam in patients with acute bacterial skin and skin structure infections. Identifier NCT01984684 Available from: https://www.clinicaltrials.gov/ct2/show/NCT01984684?term=NCT01984684&rank=1 [Accessed 8 November 2014]
   Google Scholar
• Hoover R, Lawrence L, Benedict M, et al. Pharmacokinetics of a 900 mg oral formulation of delafloxacin in healthy subjects supporting a gonorrhea phase 3 study. Presented at 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 5 – 9 September 2014; Washington. Available from: http://www.icaaconline.com/php/icaac2014abstracts/data/papers/2014/A-682.htm
   Google Scholar
• A comparative evaluation of the single-dose efficacy of oral delafloxacin versus the single-dose efficacy of an intramuscular injection of ceftriaxone in subjects with uncomplicated urogenital gonorrhea. Identifier NCT02015637 https://www.clinicaltrials.gov/ct2/show/NCT02015637?term=NCT02015637&rank=1 [Accessed 12 November 2014]
   Google Scholar
• Rubino CM, Forrest A, Bhavnani SM, et al. Delafloxacin population pharmacokinetics and covariate exploration. Presented at 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 12 – 15 September 2010; Boston, MA. Available from: http://www.melinta.com/uploads/A1-682.pdf
   Google Scholar
• Hoover R, Lawrence L, Smith C, Longcor J. Pharmacokinetics (PK) of delafloxacin (DLX) in patients with varying degrees of renal impairment in subjects with normal or impaired renal function. Presented at 53th Interscience Conference on Antimicrobial Agents and Chemotherapy; 10 – 13 September 2013; Denver, CO. Available from: http://www.icaaconline.com/php/icaac2014abstracts/data/papers/2013/late/2013_A-017e.htm
   Google Scholar
• Ding Y, Regis MD, Villet A, et al. Treatment of renal abscesses caused by Staphylococcus aureus MW2, using delafloxacin and moxifloxacin. Presented at 21st ECCMID; 7 – 10 May 2011; Milan, Italy. Available from: http://www.melinta.com/uploads/Rib-X_Delafloxacin_ECCMID-2011_P-1506.pdf
   Google Scholar
• Marra A, Bortolon E, Molstad D, et al. Evaluation of delafloxacin in rat granuloma pouch infections caused by Gram-negative pathogens [abstract A1-680]. Presented at at 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 12 – 15 September 2010; Boston, MA. Available from: http://www.melinta.com/uploads/Rib-X_Delafloxacin_ICAAC-2010_A1-680.pdf47
   Google Scholar
• Longcor J, Hopkins S, Wikler M, Lawrence L. A phase 2 safety and efficacy study of oral delafloxacin (DLX) in subjects with acute bacterial exacerbation of chronic bronchitis (ABECB). Presented at ID Week 2012; San Diego, CA. Available from: https://idsa.confex.com/idsa/2012/webprogram/Paper37662.html48
   Google Scholar
• O’Riordan W, Mehra P, Manos P, et al. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis 2014;30C:67-73
   Google Scholar
• Longcor J, Hopkins S, Lawrence L, et al. Results of a Phase 2 Study of Delafloxacin (DLX) Compared to Vancomycin (VAN) and Linezolid (LNZ) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Presented at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy ICAAC; 9 – 12 September 2012; San Francisco, CA. Available from: http://www.melinta.com/uploads/Rib-X_Delafloxacin_ICAAC-2012_L1-1663.pdf
   Google Scholar
• Longcor J, Lawrence L, Duffy E, Hopkins S. Objective measures of clinical efficacy in a phase 2b exploratory study of delafloxacin compared to vancomycin and linezolid in adults with acute bacterial skin and skin structure infections (ABSSSI). Presented at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy ICAAC; 9 – 12 September 2012; San Francisco, CA. Available from: http://www.melinta.com/uploads/Rib-X_Delafloxacin_ICAAC-2012_L1-1667c.pdf
   Google Scholar
• Soge OO, Roberts MC, Lenderman C, et al. Evaluation of in vitro activity of Delafloxacin against contemporary Neisseria gonorrhoeae isolates. Presented at 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 5 – 9 September 2014; Washington. Available from: http://www.icaaconline.com/php/icaac2014abstracts/data/papers/2014/C-1401.htm
   Google Scholar
• McEwen A, Lawrence L, Wood S, et al. Metabolism and mass balance of delafloxacin in healthy human volunteers following intravenous administration [abstract A-1956]. Presented at 52th Annual Interscience Conference on Antimcrobial Agents and Chemotherapy; 9 – 12 September 2012; San Francisco, CA, USA. Available from: http://www.melinta.com/uploads/Rib-X_Delafloxacin_ICAAC-2012_A-1956.pdf
   Google Scholar
• Lawrence L, Benedict M, Litwin J, et al. A thorough phase 1 QTc study of delafloxacin (DLX) compared with placebo and moxifloxacin (MXF) [abstract A-1958]. Presented at 52th Annual Interscience Conference on Antimcrobial Agents and Chemotherapy; 9 – 12 September 2012; San Francisco, CA, USA. http://www.melinta.com/uploads/Rib-X_Delafloxacin_ICAAC-2012_A-1958.pdf
   Google Scholar
• Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother 2003;47:3973-5
   PubMed Web of Science ®Google Scholar
• Hammerschlag MR, Roblin PM. The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolatesof Chlamydia pneumoniae. J Antimicrob Chemother 2004;54:281-2
   PubMed Web of Science ®Google Scholar